Skip to content
DataLookout
Menu

NCT06455319

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 5 more changesShow less
    • Eligibility criteria expanded, about 98 words
    • Interventions modified
    • Trial arms changed: 3 → 2
    • Study description expanded, about 39 words
    • Publications: details revised at 4 of 4 entries
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Primary completion date: Oct 2028 to Nov 2028
    • Start date changed from estimate of Oct 2025 to Nov 12, 2025
    v5
  3. Notable Start date: Jul 2025 to Oct 2025
    • Primary completion date: Jul 2028 to Oct 2028
    • Study completion date: Jul 2030 to Aug 2030
    v4
  4. Notable Start date: Apr 2025 to Jul 2025
    • Primary completion date: Apr 2028 to Jul 2028
    • Study completion date: Apr 2030 to Jul 2030
    v3
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

AUC C-peptide between ATG responder and non-responder arms
Timeframe: 12 Months
Change in 2-hr MMTT AUC C-peptide
Timeframe: 6 months

Secondary (1)

Immune and beta cell mechanistic analyses

Arms and interventions

Anti-thymocyte globulin (ATG) intravenous infusionExperimental

ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).

verapamil extended release capsuleExperimental

Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings

Drugs: Anti-thymocyte globulin (ATG), verapamil extended release capsule

Sites

2 sites in 1 country